Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Alumkal JJ, et al. Among authors: cetnar j. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323. doi: 10.1073/pnas.1922207117. Epub 2020 May 18. Proc Natl Acad Sci U S A. 2020. PMID: 32424106 Free PMC article. Clinical Trial.
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ. Hussain M, et al. Among authors: cetnar j. Invest New Drugs. 2014 Oct;32(5):904-12. doi: 10.1007/s10637-014-0099-0. Epub 2014 Apr 26. Invest New Drugs. 2014. PMID: 24764124 Free PMC article. Clinical Trial.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Graff JN, et al. Among authors: cetnar jp. Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547. Oncotarget. 2016. PMID: 27429197 Free PMC article. Clinical Trial.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ. Zhang T, et al. Among authors: cetnar j. Cancer. 2020 Oct 15;126(20):4485-4497. doi: 10.1002/cncr.33067. Epub 2020 Aug 5. Cancer. 2020. PMID: 32757302 Free PMC article. Clinical Trial.
Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS, Oldham H, Cetnar J, Taylor M. Kittai AS, et al. Among authors: cetnar j. J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180. J Immunother. 2017. PMID: 28719552 Review.
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. Aisner DL, et al. Among authors: cetnar j. Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7. Clin Cancer Res. 2018. PMID: 29217530 Free PMC article.
37 results